Antigen Is Required for Maturation and Activation of Pathogenic Anti-DNA Antibodies and Systemic Inflammation

Jeganathan Venkatesh, Hajime Yoshifuji, Daisuke Kawabata, Prameladevi Chinnasamy, Anfisa Stanevsky, Christine M. Grimaldi, Joel Cohen-Solal and Betty Diamond

J Immunol published online 28 March 2011
http://www.jimmunol.org/content/early/2011/03/28/jimmunol.1000224
Antigen Is Required for Maturation and Activation of Pathogenic Anti-DNA Antibodies and Systemic Inflammation

Jeganathan Venkatesh, Hajime Yoshifuji,1 Daisuke Kawabata,1 Pramaladevi Chinnasamy, Anfisa Stanevsky,2 Christine M. Grimaldi,3 Joel Cohen-Solal, and Betty Diamond

Systemic lupus erythematosus is an autoimmune disease characterized by autoantibodies and systemic inflammation that results in part from dendritic cell activation by nucleic acid containing immune complexes. There are many mouse models of lupus, some spontaneous and some induced. We have been interested in an induced model in which estrogen is the trigger for development of a lupus-like serology. The R4A transgenic mouse expresses a transgene-encoded H chain of an anti-DNA Ab. This mouse maintains normal B cell tolerance with deletion of high-affinity DNA-reactive B cells and maturation to immunocompetence of B cells making nonglomerulotrophic, low-affinity DNA-reactive Abs. When this mouse is given estradiol, normal tolerance mechanisms are altered; high-affinity DNA-reactive B cells mature to a marginal zone phenotype, and the mice are induced to make high titers of anti-DNA Abs. We now show that estradiol administration also leads to systemic inflammation with increased B cell-activating factor and IFN levels and induction of an IFN signature. DNA must be accessible to B cells for both the production of high-affinity anti-DNA Abs and the generation of the proinflammatory milieu. When DNase is delivered to the mice at the same time as estradiol, there is no evidence for an abrogation of tolerance, no increased B cell-activating factor and IFN, and no IFN signature. Thus, the presence of autoantigen is required for positive selection of autoreactive B cells and for the subsequent positive feedback loop that occurs secondary to dendritic cell activation by DNA-containing immune complexes. The Journal of Immunology, 2011, 186: 000–000.

S
ystemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of multiple autoantibodies (1, 2). Anti-DNA Abs are among the most significant because they are common, they are essentially diagnostic of SLE, their titers fluctuate with disease activity (3), and they contribute to tissue injury in the kidney and probably brain as well (4–6). For these reasons, they have been studied extensively.

There are several ways to induce the production of anti-DNA Abs in nonspontaneously autoimmune mice. DNA has been coupled to a protein carrier to induce production of anti-DNA Abs (7–10). In these studies, the protein is foreign and, therefore, immunogenic to T cells and the DNA functions as a hapten to activate DNA-reactive B cells. Peptide mimotopes of DNA have been exploited to induce a T cell-dependent anti-DNA response (11–13). In some studies, apoptotic cells have been administered to mice and shown to induce production of an anti-DNA response (14–18). It has been demonstrated that many perturbations of the immune system that diminish the clearance of apoptotic debris can stimulate the production of anti-DNA Abs (19–23). The apoptotic material contains endogenous ligands for TLRs, and so may transform tolerogenic dendritic cells (DCs) into immunogenic DCs and trigger an immune response to self Ag (24–28). Once anti-DNA Abs are present, they form DNA-containing immune complexes that, when internalized by DCs, can activate TLR9 and excite production of B cell-activating factor (BAFF) and IFN-α (29, 30). When the immune complexes are internalized by DNA-specific B cells, the B cells can be activated through TLR9 engagement to secrete pathogenic Ab.

We have been studying the induction of anti-DNA Abs in the R4A transgene (Tg) BALB/c mouse that harvests an IgG2b H chain of an anti-DNA Ab (31, 32). Approximately 90% of B cells express an endogenous H and L chain, and 10% express the R4A Tg H chain with a spectrum of L chains. Tg-expressing B cells undergo a normal maturation program in the bone marrow (33). Under normal conditions, B cell tolerance is maintained (33–36). B cells expressing the R4A H chain along with a L chain that produces high-affinity DNA binding are deleted at both the immature stage in the bone marrow and the transitional stage in the spleen (35, 36). Many B cells expressing the R4A H chain along with a L chain producing a low-affinity DNA binding are allowed to mature to immunocompetence, as are B cells expressing the R4A H chain along with a L chain that confers no DNA binding (33, 34, 37).

When R4A Tg BALB/c mice are given estradiol (E2) pellets to achieve a sustained serum concentration of 75–100 pg/ml, the R4A-expressing high-affinity DNA-reactive B cells survive negative selection and mature to immunocompetence as marginal zone (MZ) B cells (38). Our studies have shown that E2 causes a decrease in BCR signaling strength and reduced BCR-mediated
apoptosis of immature and transitional B cells (36, 39). In this study, we asked whether the E2-induced lupus-like serology was accompanied by other features of SLE, such as elevated BAFF levels and an IFN signature. We further asked whether Ag was needed for the proinflammatory milieu and the positive selection and activation of high-affinity DNA-reactive B cells. We demonstrate that Ag is critical to the generation of the proinflammatory milieu. It is also required for positive selection of pathogenic autoreactive B cells; the diminished negative selection alone that is secondary to reduced BCR signaling is not alone sufficient for the development of pathogenic autoreactivity. These observations have important clinical implications.

Materials and Methods

Mice, hormone treatment, and therapeutic regimens

R4A Tg BALB/c mice, described previously (31), were bred and maintained at the Feinstein Institute for Medical Research. All animal studies were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee. Sixty-day time-release pellets (Innovative Research of America) containing E2 (0.18 mg) or placebo (P; vehicle control) were implanted beneath the skin of 8- to 10-wk-old female mice. The E2 pellets maintain serum E2 concentrations of 75–100 pg/ml (34). To avoid the problem of fluctuations in the endogenous E2 levels that occur in P-treated mice, all mice were ovariectomized prior to implantation of pellets. For experimental studies, mice were divided into four groups, as follows: P, E2, E2 plus DNase, and E2 plus heat-inactivated (HI) DNase. DNase treatment of mice was performed as reported by Macanovic et al. (40). Briefly, mice were injected i.p. daily with 450 μg bovine pancreatic DNase (Sigma-Aldrich) or HI enzyme (68˚C for 15 min) in 200 μl saline for 6 wk. Before the start of treatment, and at weekly intervals until 6 wk, animals were bled by retro-orbital puncture. Urine was collected at both the beginning and the end of the experiment to examine the level of proteinuria.

Flow cytometry

Splenocytes from R4A Tg mice treated with P, E2, E2 plus DNase, and E2 plus HI DNase were isolated, Fc blocked, and stained with PerCP-labeled anti-DNase + Ab (BD Pharmingen), and allophycocyanin-labeled anti-AA4.1 Ab (eBioscience) at 4˚C for 30 min and washed with PBS. The stained cells were analyzed by flow cytometry using an LSR II instrument (BD Biosciences), and the data were analyzed using FlowJo software (Tree Star).

Measurement of dsDNA in plasma

dsDNA was measured in the plasma of the experimental mice using picogreen dsDNA reagent (Invitrogen), according to the manufacturer’s instructions. Different dilutions of plasma in 100 μl Tris-EDTA buffer were incubated with 100 μl picogreen assay reagent. The mixture was incubated for 5 min at room temperature, the fluorescence was measured using a fluorescence microplate reader, and standard fluorescence wave-lengths (excitation =480 nm, emission =520 nm) were used. The dsDNA in the samples was quantitated by means of a standard curve using lambda DNA (25 pg/ml to 25 ng/ml) as the standard. Appropriate controls such as plasma from BALB/c mice and plasma from New Zealand Black/White (NZB/W) young and sick mice were used to validate the picogreen assay.

Measurement of serum DNase

The levels of DNase protein in the serum of mice were measured by a sandwich ELISA. ELISA plates (Costar) were coated with anti-DNase Ab (1:1000 dilution). Serum samples at different dilutions were added to the plates subsequent to blocking with 1.0% BSA/PBS, followed by the addition of biotinylated anti-DNase + Ab. DNase protein levels were detected using streptavidin coupled to alkaline phosphatase (AP, 1:1000 dilution). A standard curve with purified DNase was generated to calculate the concentration of DNase in serum.

Anti-DNase Abs in serum

Abs to DNase in mice sera were assayed by ELISA after 6 wk of treatment with P, E2, E2 plus DNase, or E2 plus HI DNase. Bovine pancreatic DNase-coated plates (10 μg/ml) were blocked with 1.0% BSA/PBS, followed by the addition of serum (1:250 dilution) from R4A Tg mice treated with P, E2, E2 plus DNase, and E2 plus HI DNase for 6 wk. The plates were probed with AP-conjugated anti-mouse IgG (1:1000 dilution), developed with AP substrate, and measured at 405 nm.

Analysis of Vc-Jk L chain genes by single-cell RT-PCR

Splenocytes from three mice in each experimental group were stained with Abs specific for B220, IgG2b, and AA4.1, and the mature (B220*IgG2b*AA4.1+) and immature (B220*IgG2b**AA4.1+) Tg + B cells were sorted as single cells into 96-well plates using a FACS Aria cell sorter (BD Biosciences). cDNA was prepared from the single cells, and the Vc-Jk L chain genes were amplified by two rounds of PCR, as previously described (41), using the following primers: universal Vc, 5’-GGCTGCGAGTT- CAGTGGCAATGCTWGGRAC-3’ plus C region primer (Cc) (first round), 5’-TGATGGTGGGAGAATG-3’ and Cc (second round), 5’- AAGATGACAGTTGG-3’. Sequence analysis of the PCR products was performed using the second-round Cc primer (Genewiz) subsequent to exo-shrimp alkaline phosphatase treatment (USB Biochemicals).

Real-time PCR

Splenocyte total RNA was isolated using the RNeasy kit from Qiagen, and cDNA was synthesized using the iScript cDNA synthesis kit (Bio-Rad). Real-time PCR was performed with a Roche 480 light cycler using Roche 480 master mix (Roche Applied Science) and TaqMan primer/probe sets (Applied Biosystems). The relative expression of BAFF, type I IFNs α and β, and the IFN-regulated genes ms-1 and if202b was determined in comparison with polymerase (RNA) II (DNA-directed) polypeptide A (polr2a). Data were analyzed using the Pfaffl method (42).

Measurement of serum BAFF

An ELISA was performed to determine serum BAFF levels, as described previously (41). Ninety-six–well plates were coated with 5 μg/ml anti-mouse BAFF mAb (clone 5A8; Apotech) overnight at 4˚C and blocked with 5% BSA/PBS. Serial dilutions of mouse sera or mouse BAFF (Apotech) were added to the wells, followed by 10 μg/ml biotinylated anti-mouse BAFF mAb (clone 1C9; Apotech) and HRP-labeled streptavidin. The plates were developed with HRP substrate, and the OD was measured at 450 nm.

Anti-dsDNA Ab ELISA

Serum anti-DNA Ab levels were determined, as previously described (43). Immulon 2HB 96-well plates (Thermo LabSystems) were coated with 100 μl/ml sonicated calf thymus DNA that had been passed through a nitrocellulose filter to remove sDNA. Mouse serum at different dilutions was added to plates after blocking with 1.0% BSA/PBS. IgG2b+ anti-DNA Abs were detected using AP-conjugated mouse IgG2b Ab (Southern Bio-technology). Purified R4A mAb was used (1–50 μg/ml) to generate a standard curve for calculating the concentration of anti-dsDNA Abs in the sera.

DNA inhibition ELISAs

The linear range of DNA reactivity was determined by the generation of dilution curves for serum samples from three each E2-, E2 plus DNase-, and E2 plus HI-inactivated DNase-treated R4A Tg mice. Serum samples were diluted (1:100) and preincubated with various concentrations of sonicated DNA (~2,0 kb in length) for 2 h at 37˚C, and the remaining DNA reactivity was measured by DNA ELISA. The range of relative affinities of the anti-DNA Abs present in the sera was calculated, as previously described (44).

Serum treatment of DCs

Splenic DCs isolated from 20 10-wk-old BALB/c mice using CD11c-coated microbeads (Miltenyi Biotec) were resuspended in RPMI 1640 complete medium containing 10% FBS and preincubated with various concentrations of sonicated DNA (~2,0 kb in length) for 2 h at 37˚C, and the remaining DNA reactivity was measured by DNA ELISA. The range of relative affinities of the anti-DNA Abs present in the sera was calculated, as previously described (44).

Renal pathology

Kidneys from the different experimental groups of R4A Tg mice (three per group) described above were fixed in formalin, paraffin embedded, sectioned (10 μm thickness), stained with biotinylated anti-mouse IgG, and developed with an AP ABC detection kit (Vector Laboratories).
Glomerular IgG deposition in kidney sections was visualized under a Zeiss microscope at original magnifications ×5 and ×20. The number of glomeruli present in three different microscopic fields for each sample was determined. Three mice in each group were analyzed, and the mean percentage of positive glomeruli is shown. The investigator was blinded to the origin of the kidneys.

Analysis of proteinuria

Proteinuria was measured using Bayer reagent strips (Bayer), according to the manufacturer’s instructions, as well as by measuring total protein in the urine using the Coomassie blue reagent (Pierce).

Studies in SLE have shown that DNA-containing immune complexes can activate DCs in vitro to produce both BAFF and IFN-α, which has previously been demonstrated to deposit in kidneys of SCID mice, was used as a positive control (45).

Statistical analysis

Statistical analysis was performed using unpaired Student’s t test, the exact Kruskal-Wallis test, and Fisher’s exact tests, used as appropriate. A p value < 0.05 was considered statistically significant.

Results

Generation of a proinflammatory milieu by E2 administration

R4A Tg mice harbor the H chain of the nephritogenic R4A anti-DNA Ab (31). These mice normally maintain B cell tolerance; upon exposure to increased levels of E2, they display an altered B cell repertoire with enhanced survival and activation of high-affinity DNA-reactive B cells. Elevated anti-dsDNA Ab levels, immune complex deposition in kidneys, and subsequent proteinuria can be observed, peaking ~6 wk after initiation of treatment and remaining high for months thereafter (33) (J. Venkatesh, E. Peeva, and B. Diamond, unpublished observations). The mice exhibit minimal inflammation in the kidney despite the presence of IgG deposition, presumably because they lack the genetic background necessary for renal inflammation. Hence, the R4A Tg mouse model is a useful model system to study some downstream effects of anti-DNA Abs in a host devoid of pre-existing immunologic abnormalities.

Studies in SLE have shown that DNA-containing immune complexes can activate DCs in vitro to produce both BAFF and IFN-α, leading to the increased expression of multiple IFN-inducible genes, termed the IFN signature (46–49). Other studies have suggested that RNA-containing immune complexes are more contributory to DC activation and the induction of an IFN signature (50). Still another study performed in humans has suggested a genetic predisposition to increased type 1 IFN production that may precede autoantibody production (51). We have previously shown increased BAFF mRNA in E2-treated R4A Tg mice (36). In this study, we asked whether the induction of R4A-encoded anti-DNA Abs was sufficient to induce inflammatory features of SLE.

Serum BAFF levels were measured by ELISA. Mice receiving E2 pellets exhibited an increase in BAFF mRNA in splenocytes, as previously shown (Fig. 1A), and increased serum BAFF levels (Fig. 1B). It is known that B cell lymphopenia leads to increased BAFF levels (52). We, therefore, ascertained that there was no decrease in total B cell number secondary to the E2 administration (P, 586,352 ± 56,301; E2, 509,414 ± 14,049 B cells per 10⁸ splenocytes), although we have previously shown a decrease in transitional B cells in the spleen (38) and others have shown an E2-induced decrease in B cell lymphopoiesis in the bone marrow (53). We also assayed for expression of type 1 IFNs (IFN-α,β) in splenic DCs treated with serum from P- and E2-treated R4A Tg mice, as well as ifi202b and mx-1, two prominent genes in the IFN signature. An increase in the mRNA of the IFN-inducible genes ifi202b and mx-1 in splenocytes from E2-exposed R4A Tg mice was observed (Fig. 1C, 1D). Cultured splenic DCs treated with serum from E2-exposed R4A Tg mice displayed an upregulation in the transcription of IFN-α and IFN-β genes (Fig. 1E, 1F).

To determine whether E2 was directly responsible for the induction of a proinflammatory milieu or whether the production of proinflammatory cytokines was secondary to the presence of DNA-containing immune complexes, R4A Tg mice were injected with 450 μg bovine pancreatic DNase daily i.p. for 5 wk during the period of treatment with E2 to reduce the availability of DNA. To confirm that the exogenous DNase altered serum levels of DNase, a DNase ELISA was performed. An increase in serum DNase
levels was observed throughout the treatment period, stabilizing by 3 wk (Fig. 2A). Furthermore, bovine pancreatic DNase was biologically active in mouse circulation, as determined by a decrease in plasma DNA detectable by the dsDNA-specific picogreen assay (Fig. 2B). Treatment with bovine pancreatic DNase resulted in the generation of anti-DNase Abs in R4A Tg mice. R4A Tg mice were treated with P, E2, E2 plus DNase, and E2 plus HI DNase for 6 wk. After 6 wk, anti-DNase Abs were detected in serum by ELISA using serum at 1:250 dilution. Four to seven mice per group were used for the studies.

Both the increased BAFF and the induction of type 1 and type 2 IFNs as well as IFN signature were reversed by administration of DNase, but not by HI DNase, demonstrating that the strength of the BCR signaling is diminished by E2 exposure (36). Engagement of the BCR following E2 exposure results in a lower calcium flux and decreased ERK phosphorylation (36). This is associated with an expansion of transgene-expressing B cells and more high-affinity DNA-reactive B cells with a MZ phenotype (35, 38). Because we know the repertoire of L chains that fails to generate DNA binding, the repertoire that generates low-affinity DNA binding, and the repertoire that generates high-affinity DNA binding (Table I) (33, 34), we can examine L chain usage in transgene-expressing B cells and determine how different manipulations of the mice alter B selection. Usually, B cells expressing L chains such as Vk1A-Jk1, Vk1A-Jk4, and Vk10-Jk5 that generate high-affinity DNA-reactive B cells, with apparent affinities of $10^{-8}$ to $10^{-9}$ M, are eliminated by deletion in R4A mice as immature B cells in the bone marrow and at the transitional stage of B cell maturation in the spleen, whereas B cells expressing L chains such as Vk1A-Jk5, Vk21-Jk1, and Vk21-Jk2 L chains that generate low-affinity DNA-reactive B cells (Table I) are less susceptible to negative selection, and many of these latter B cells, with apparent affinities of $10^{-6}$ to $10^{-7}$ M, survive and are selected into the mature, immunocompetent repertoire (35).

Because essentially all IgG2b-producing B cells express the R4A transgene (41), we can analyze L chain expression in transgene-expressing B cells by focusing on IgG2b+ B cells. Using single-cell PCR analysis, we have demonstrated in earlier studies that E2 treatment of R4A Tg mice leads to a shift in the DNA-reactive B cell repertoire, with an increase in high-affinity DNA-reactive B cells in both the transitional and mature B cell repertoire and

**FIGURE 2.** Bovine pancreatic DNase is biologically active in vivo. A, A detectable increase in serum DNase levels was observed upon administration of 450 µg bovine pancreatic DNase in R4A Tg mice as measured by ELISA. B, A significant decrease in circulating plasma dsDNA levels was observed in E2-treated R4A Tg mice administered DNase, but not HI DNase compared with E2-treated R4A Tg mice. As controls for the picogreen assay, plasma dsDNA levels were measured in BALB/c mice and young and sick NZB/W mice. C, Treatment with bovine pancreatic DNase resulted in the generation of anti-DNase Abs in R4A Tg mice. R4A Tg mice were treated with P, E2, E2 plus DNase, and E2 plus HI DNase for 6 wk. After 6 wk, anti-DNase Abs were detected in serum by ELISA using serum at 1:250 dilution. Four to seven mice per group were used for the studies.
a decrease in low-affinity DNA-reactive B cells in the mature B cell subset (35). Because we demonstrated that DNase led to an elimination of the effects of DNA-containing immune complexes, we were interested in ascertaining whether DNase treatment also led to an alteration in the E2-induced shift in the B cell repertoire in R4A Tg mice or merely led to a reduction in the amount of Ag available to form immune complexes. L chain sequences were, therefore, determined in both transitional and mature Tg B cells isolated from P-, E2-, E2 plus DNase-, or E2 plus HI DNase-treated R4A Tg mice (three in each group, yielding a total of 110, 114, 135, and 114 sequences). We identified 23 different V\textsubscript{k}L chains in all experimental groups, 10 of which were commonly expressed in all the groups. In R4A mice, V\textsubscript{k}4/5 L chains predominated (40%), followed by V\textsubscript{k}1 (22%) and V\textsubscript{k}21 (12%) L chains. In contrast, E2 treatment resulted in a predominant V\textsubscript{k}1 L chain usage (45%), followed by V\textsubscript{k}21 (21%) and V\textsubscript{k}9/10 (10%) L chains, as identified in our previous studies (35). Interestingly, DNase treatment shifted the B cell repertoire toward that observed in P-treated mice with predominant usage of V\textsubscript{k}4/5 L chains, followed by V\textsubscript{k}1 and V\textsubscript{k}21 L chains.

The transitional and mature R4A-expressing B cells in E2-treated mice expressed L chains that generate high-affinity DNA reactivity at a frequency of 23 and 29%, respectively, whereas only 12 and 8%, respectively, of immature and transitional Tg B cells in P-treated mice expressed L chains that give rise to high-affinity DNA-reactive B cells. Upon DNase administration, E2-treated R4A Tg mice expressed L chains that confer high-affinity DNA reactivity in 13 and 11% of transitional and mature B cells, respectively (Table II). HI DNase treatment did not alter the E2-induced repertoire, demonstrating that active DNase was required for the reversion of the B cell repertoire to that present in P-treated mice.

As previously reported, there was no effect of E2 on the frequency of low-affinity transitional DNA-reactive B cells. In E2-treated mice, there were fewer mature Tg-expressing B cells with L chains that generate low-affinity DNA-reactive B cells than in P-treated mice (Table II). We have previously reported this and believe it reflects a competition for Ag with fewer low-affinity DNA-reactive B cells when high-affinity B cells are present. DNase treatment, but not HI DNase treatment, resulted in a restoration of low-affinity DNA-reactive B cells in the mature Tg B cells. Just as the decrease in the frequency of low-affinity DNA-reactive B cells in E2-treated R4A Tg mice probably reflects a failure of these low-affinity DNA-reactive B cells to compete for entrance into follicular niches when high-affinity DNA-reactive B cells escape tolerance, the increase in low-affinity DNA-reactive B cells probably occurs when high-affinity B cells do not survive (35). Taken together, these data suggest that DNase treatment of E2-exposed R4A Tg mice causes preferential elimination of high-affinity DNA-reactive B cells and restoration of low-affinity DNA-reactive B cell population. Moreover, it suggests that the low BCR signal strength is not by itself sufficient to change the B cell repertoire; rather, Ag is required to mediate positive selection.

We have demonstrated previously that E2 exposure of R4A Tg mice displayed decreased number of transitional B cells and a shift in T1:T2 ratio, with more T2 cells (38). An increase in the mature B cell population that is comprised of MZ and follicular B cells was observed and the percentage of MZ B cells was doubled (38). We wanted to determine whether DNase treatment could abrogate E2-induced changes in peripheral B cell development. Interestingly, treatment with DNase, but not HI DNase, diminished the 2-fold increase in the MZ B cells seen in E2-treated R4A Tg mice and the transitional T1 and T2 B cells were restored to that observed in the placebo group (Fig. 3).

**Serum titers of anti-DNA Abs**

Surprisingly, administration of DNase to E2-treated R4A Tg mice did not decrease the serum titers of anti-DNA Ab to baseline levels (Fig. 4A). Because we knew that the DNase-treated mice harbored few high-affinity DNA-reactive B cells, we reasoned that the Ab titers reflected low-affinity Abs that were not bound to DNA in serum. To further ascertain that administration of DNase to E2-treated R4A mice led to a loss of high-affinity DNA binding, we measured the apparent affinities of the anti-dsDNA Abs in the sera of E2-, E2 plus DNase-, and E2 plus HI DNase-treated R4A Tg mice.

### Table I. Relative affinities of DNA-reactive B cells from R4A Tg mice

<table>
<thead>
<tr>
<th>V\textsubscript{k}J\textsubscript{c} Usage</th>
<th>Relative Affinity*</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>V\textsubscript{k}1A-J\textsubscript{c}1</td>
<td>9.1 × 10^{-8}</td>
<td>33, 37</td>
</tr>
<tr>
<td>V\textsubscript{k}1A-J\textsubscript{c}5</td>
<td>4.5 × 10^{-9}</td>
<td>33</td>
</tr>
<tr>
<td>V\textsubscript{k}1A-J\textsubscript{c}4</td>
<td>4.2 × 10^{-8}</td>
<td>37</td>
</tr>
<tr>
<td>V\textsubscript{k}10-J\textsubscript{c}5</td>
<td>6.6 × 10^{-8}</td>
<td>34</td>
</tr>
<tr>
<td>V\textsubscript{k}21-J\textsubscript{c}1</td>
<td>2.2 × 10^{-6}</td>
<td>33</td>
</tr>
<tr>
<td>V\textsubscript{k}21-J\textsubscript{c}2</td>
<td>9 × 10^{-6}</td>
<td>33</td>
</tr>
<tr>
<td>V\textsubscript{k}4/5-J\textsubscript{c}5</td>
<td>ND</td>
<td>34</td>
</tr>
<tr>
<td>V\textsubscript{k}19-J\textsubscript{c}5</td>
<td>ND</td>
<td>34</td>
</tr>
<tr>
<td>V\textsubscript{k}24/25-J\textsubscript{c}2</td>
<td>ND</td>
<td>34</td>
</tr>
</tbody>
</table>

*The relative affinity of the R4A H chain paired with each L chain was determined in previous studies by inhibition ELISA (33, 34, 37).

### Table II. Frequency of high-affinity and low-affinity DNA-reactive B cells in R4A Tg mice treated with E2 with or without DNase

<table>
<thead>
<tr>
<th>Placebo (%)</th>
<th>E2 (%)</th>
<th>E2 + DNase (%)</th>
<th>E2 + HI DNase (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transitional Mature</td>
<td>650 (12)</td>
<td>12/52 (23)*</td>
<td>8/63 (12.6)*</td>
</tr>
<tr>
<td>High affinity</td>
<td>5/60 (8.3)</td>
<td>18/62 (27.7)*</td>
<td>8/72 (11.1)*</td>
</tr>
<tr>
<td>Low affinity</td>
<td>11/60 (18)</td>
<td>5/62 (8)*</td>
<td>18/72 (25)</td>
</tr>
</tbody>
</table>

A significant increase in high-affinity anti-DNA B cells in R4A Tg mice treated with E2 was observed and was abrogated by treatment with DNase, but not HI DNase. Fisher’s exact test was used to analyze significance between the various treatment groups compared with the P-treated group.

*p < 0.05.

ns, Not significant.
in proteinuria (Fig. 4D, 4E); HI DNase failed to affect immune complex deposition (Fig. 4B, 4C). Whereas these data were consistent with the observation that the anti-DNA Abs in E2 plus DNase-treated mice were of low affinity, they might also reflect an enzymatic removal of accessible Ag from the glomeruli. We, therefore, asked directly whether the serum of E2-exposed DNase-treated mice had glomerulotropic potential.

The parental R4A Ab with an affinity of $10^{-8}$ has been shown to deposit in the glomeruli of the kidneys in SCID mice when administered i.p. (44). This approach permits a study of the potential pathogenicity of anti-DNA Abs. To confirm that the administration of DNase to E2-treated R4A Tg mice resulted in the accumulation of low-affinity anti-DNA Abs that are nonglomerulotropie, the serum from E2-treated R4A Tg mice given DNase was assayed for glomerular deposition in SCID mice. As shown in Fig. 5, serum from E2-treated R4A Tg mice bound strongly to glomeruli; however, the serum from E2 plus DNase-treated R4A Tg mice did not deposit in kidneys of SCID mice. IgG in serum

![Figure 3](http://www.jimmunol.org/)

**FIGURE 3.** DNase treatment abrogates E2-induced changes in B cell development in R4A Tg mice. Administration of DNase resulted in reversal of E2-induced increase in MZ B cells (A) and transitional B cells (B). However, HI DNase did not affect E2-induced changes in MZ and transitional B cells. MZ B cells were identified as CD21<sup>high</sup>CD23<sup>neg</sup>CD24<sup>low</sup>, and transitional B cells were identified as CD21<sup>low</sup>CD24<sup>high</sup> (T1) and CD21<sup>high</sup>CD24<sup>high</sup> (T2). Five mice were used in each group.

![Figure 4](http://www.jimmunol.org/)

**FIGURE 4.** Treatment with DNase alleviates E2-induced target organ damage despite persistently elevated serum anti-dsDNA Ab titers. A. Serum anti-dsDNA Ab levels in R4A Tg mice treated with E2, E2 plus DNase, and E2 plus HI DNase for 6 wk. A significant increase in anti-dsDNA Ab levels in sera of R4A Tg mice was observed after implantation with E2 pellets and was unaltered by DNase administration. B. Glomerular IgG deposition in R4A Tg mice following administration of E2, E2 plus DNase, or E2 plus HI DNase. C. The number of positive glomeruli was counted in three different microscopic fields in each section. The average number of positive glomeruli in three individual mice in each group is represented. DNase treatment, but not HI DNase treatment of E2-treated R4A Tg mice resulted in a marked decrease in Ab deposition in the kidney. A representative of five mice per group is shown at original magnification ×5. Proteinuria was measured in five P-, E2-, E2 plus DNase-, and E2 plus HI DNase-treated R4A Tg mice using reagent strips (D) and by the Coomassie blue reagent (E). Proteinuria was increased in E2-treated R4A Tg mice and was diminished upon administration of DNase. Treatment with HI DNase did not affect the E2-induced increase in proteinuria levels.
from E2 plus HI DNase-treated R4A Tg mice bound to glomeruli similar to IgG in serum from E2-treated R4A Tg mice (Fig. 5). These data corroborate the repertoire analysis and the analysis of serum Ab affinity.

Discussion

It is of considerable interest that the presence of anti-DNA Abs is sufficient to increase BAFF levels in the serum and to induce an IFN signature in splenocytes. That DNA-containing immune complexes can induce increased BAFF expression in DCs has been shown in in vitro studies (54). The data reported in this study demonstrate that a proinflammatory milieu can be generated in a non-spontaneously autoimmune host just by virtue of inducing high-affinity anti-DNA Abs. From our studies it is apparent that E2 alone did not directly cause the proinflammatory milieu, as administration of DNase to E2-treated mice totally abrogated the inflammatory response. This observation also confirms that some anti-DNA Abs exist in immune complexes and that the availability of DNA in a mouse with no apparent defect in clearance of apoptotic debris is sufficient to form proinflammatory immune complexes. Furthermore, it supports the hypothesis that TLR9 activation can lead to the upregulation of inflammatory cytokines. This is a contentious issue, as some, but not all, lupus-prone strains of mouse display improvement with a deletion of TLR9 (55–58). Similarly, studies of human SLE have been contradictory, with some investigators suggesting that DNA-containing immune complexes induce the IFN signature and others arguing that R4A-containing immune complexes, which activate TLR7, are more important (25, 26, 59). This has also been shown that relatives of patients with SLE exhibit high serum levels of type 1 IFN, suggesting that there is a predisposition to enhanced IFN production in SLE patients (51). This is consistent with an IFN regulatory factor 5 susceptibility allele in this disease, which has been identified in genome-wide scans (60). This study, however, shows that elevated serum titers of high-affinity anti-DNA Abs are necessary to induce DC activation in a host with unimpaired clearance of apoptotic debris and no pre-existing overexpression of inflammatory cytokines. Because it now seems that the systemic immune activation present in SLE may contribute to accelerated atherosclerosis (61), the fact that anti-DNA Abs alone can initiate an inflammatory cascade may inform therapeutic strategies. It should be noted that E2-treated mice given either DNase or HI DNase might have circulating immune complexes composed of enzyme and anti-DNase Ab. These complexes did not appreciably alter the inflammatory milieu as E2- and E2 plus HI DNase-treated mice appear similar.

It is apparent from these studies that the production of high-affinity DNA-reactive Abs triggers a positive feedback loop. The ensuing elevation in BAFF can function to facilitate the survival and maturation to immunocompetence of more autoreactive B cells. Such a model has clearly been demonstrated in mouse studies and is highly likely to apply in humans as well (62). This would explain the high BAFF levels even in patients who are not B cell lymphopenic.

It was perhaps most surprising that the enhanced number of high-affinity DNA-reactive B cells in the transitional and mature B cell compartments of E2-treated mice depends on the presence of DNA. Having previously shown that E2 exposure diminishes the strength of BCR signaling (36), we assumed that there would be less negative selection of high-affinity DNA-reactive B cells independent of the presence of Ag. The data reported in this study, however, strongly suggest that differentiation to a mature state requires positive selection. Thus, in the absence of an adequate exposure to DNA, high-affinity DNA-reactive B cells did not mature to immunocompetence, despite a lower BCR signaling capacity and reduced negative selection.

Low-affinity anti-DNA Abs do not initiate renal inflammation and do not form immune complexes that activate TLR9. It is also possible that the low-affinity Abs are not present in immune complexes, whereas the high-affinity Abs form immune complexes in plasma, and that these differences may contribute to the difference in glomerular deposition. In parallel, it is clear that some individuals with high titers of anti-DNA Abs do not develop renal disease (63). These individuals may have primarily low-affinity Abs. These data suggest that it may be important to screen patients for the presence of high-affinity anti-DNA Abs to determine
appropriate treatment and response to therapy. The current ELI-SAs used in most clinical assays do not distinguish between high- and low-affinity Abs.

These studies also suggest that DNase might be an effective therapy in SLE. Whereas we cannot know that active DNase functions only to decrease Ag load, it clearly led to a reduction in plasma DNA. The DNaseI-deficient mouse develops a SLE-like disease (64). A few patients with SLE have been shown to be DNase1 deficient (65), and some patients have been reported to have Abs to DNase (66). One study in NZB/W mice showed a short-term delay in disease onset when DNase treatment was begun prior to disease onset and even showed reduced renal pathology if therapy is begun after onset of disease (39). A second study failed to replicate a reduction in renal disease, but did show a decrease in DNA-reactive B cells, similar to what was seen in the data reported in this study (67). It is possible that the limited success of DNase treatment reflected the production of Abs to exogenous DNase.

The first trial of DNase in patients with SLE was reported in 1961 (68). Eight patients were treated with bovine enzyme, which was highly immunogenic and led to some severe Arthus reactions and early termination of the study. Almost 40 years later, a second clinical trial was initiated (69). Clinical measurements included serum cytokines, serum anti-DNA Abs, and anti-DNA–secreting B cells in peripheral blood. None of these parameters was significantly affected, but there was no detectable increase in serum DNA activity in the patients studied. Thus, it remains unresolved whether DNase therapy might be a nonimmunosuppressive therapeutic strategy in SLE. The studies reported in this work strongly support the need to revisit this question.

Acknowledgments

We thank Sylvia Jones for expert secretarial assistance.

The authors disclose no conflicts of interest.

References

6. DiGiorgio, L. A., K. N. Konstantinov, S. C. Lee, J. A. Hardin, B. T. Volpe, and B. Diamond. 2001. A subset of lupus anti-DNA antibodies cross-reacts with the recombinant murine DNase1 deficient (65), and some patients have been reported to have Abs to DNase (66). One study in NZB/W mice showed a short-term delay in disease onset when DNase treatment was begun prior to disease onset and even showed reduced renal pathology if therapy is begun after onset of disease (39). A second study failed to replicate a reduction in renal disease, but did show a decrease in DNA-reactive B cells, similar to what was seen in the data reported in this study (67). It is possible that the limited success of DNase treatment reflected the production of Abs to exogenous DNase.

The first trial of DNase in patients with SLE was reported in 1961 (68). Eight patients were treated with bovine enzyme, which was highly immunogenic and led to some severe Arthus reactions and early termination of the study. Almost 40 years later, a second clinical trial was initiated (69). Clinical measurements included serum cytokines, serum anti-DNA Abs, and anti-DNA–secreting B cells in peripheral blood. None of these parameters was significantly affected, but there was no detectable increase in serum DNA activity in the patients studied. Thus, it remains unresolved whether DNase therapy might be a nonimmunosuppressive therapeutic strategy in SLE. The studies reported in this work strongly support the need to revisit this question.

Acknowledgments

We thank Sylvia Jones for expert secretarial assistance.

The authors disclose no conflicts of interest.

References

6. DeGiorgio, L. A., K. N. Konstantinov, S. C. Lee, J. A. Hardin, B. T. Volpe, and B. Diamond. 2001. A subset of lupus anti-DNA antibodies cross-reacts with the recombinant murine DNase1 deficient (65), and some patients have been reported to have Abs to DNase (66). One study in NZB/W mice showed a short-term delay in disease onset when DNase treatment was begun prior to disease onset and even showed reduced renal pathology if therapy is begun after onset of disease (39). A second study failed to replicate a reduction in renal disease, but did show a decrease in DNA-reactive B cells, similar to what was seen in the data reported in this study (67). It is possible that the limited success of DNase treatment reflected the production of Abs to exogenous DNase.

The first trial of DNase in patients with SLE was reported in 1961 (68). Eight patients were treated with bovine enzyme, which was highly immunogenic and led to some severe Arthus reactions and early termination of the study. Almost 40 years later, a second clinical trial was initiated (69). Clinical measurements included serum cytokines, serum anti-DNA Abs, and anti-DNA–secreting B cells in peripheral blood. None of these parameters was significantly affected, but there was no detectable increase in serum DNA activity in the patients studied. Thus, it remains unresolved whether DNase therapy might be a nonimmunosuppressive therapeutic strategy in SLE. The studies reported in this work strongly support the need to revisit this question.

Acknowledgments

We thank Sylvia Jones for expert secretarial assistance.

The authors disclose no conflicts of interest.

References

6. DeGiorgio, L. A., K. N. Konstantinov, S. C. Lee, J. A. Hardin, B. T. Volpe, and B. Diamond. 2001. A subset of lupus anti-DNA antibodies cross-reacts with the recombinant murine DNase1 deficient (65), and some patients have been reported to have Abs to DNase (66). One study in NZB/W mice showed a short-term delay in disease onset when DNase treatment was begun prior to disease onset and even showed reduced renal pathology if therapy is begun after onset of disease (39). A second study failed to replicate a reduction in renal disease, but did show a decrease in DNA-reactive B cells, similar to what was seen in the data reported in this study (67). It is possible that the limited success of DNase treatment reflected the production of Abs to exogenous DNase.

The first trial of DNase in patients with SLE was reported in 1961 (68). Eight patients were treated with bovine enzyme, which was highly immunogenic and led to some severe Arthus reactions and early termination of the study. Almost 40 years later, a second clinical trial was initiated (69). Clinical measurements included serum cytokines, serum anti-DNA Abs, and anti-DNA–secreting B cells in peripheral blood. None of these parameters was significantly affected, but there was no detectable increase in serum DNA activity in the patients studied. Thus, it remains unresolved whether DNase therapy might be a nonimmunosuppressive therapeutic strategy in SLE. The studies reported in this work strongly support the need to revisit this question.